Immune Pharmaceuticals Inc. (IMNP ) stock prices updated...
 

Immune Pharmaceuticals Inc. stock price

Immune Pharmaceuticals Inc. latest news:


  • 09/27/2017 06:21:45

    Immune Pharmaceuticals shares surge 75% on positive mid-stage clinical trial results

    Immune Pharmaceuticals Inc. shares surged 75% in premarket trade Wednesday after the company said early results from a phase 2 clinical trial for moderate-to-severe bullous pemphigoid were positive. Company shares closed at $1.20 on Tuesday. The results, which came from the first six patients enrolled in the clinical trial for Immune Pharmaceuticals' bertilimumab, found a decline in patients' total activity score for the condition of 85%. Patients' improvement was "rapid," the company said, with the activity score declining on average by 72% by day 42. Bullous pemphigoid is a rare skin condition that consists of large blisters that can be life-threatening, especially for already-sick older individuals, who the condition commonly afflicts, according to the Mayo Clinic. The company said it will continue to enroll patients in the phase 2 trial, with target enrollment of 12 to 15 patients, and has plans for a larger clinical trial. Immune Pharmaceuticals shares have declined 57.5% over the last three months, compared with a 3.2% rise in the S&P 500 .Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • More trends:

    ImmunoGen, Inc.IMGN | Immunomedics, Inc.IMMU | Impax Laboratories, Inc.IPXL | Imprimis Pharmaceuticals, Inc.IMMY | INC Research Holdings, Inc.INCR | inContact, Inc.SAAS | Incyte CorporationINCY | Independent Bank Corp.INDB | Independent Bank CorporationIBCP | Independent Bank Group, IncIBTX |